Drugs / TransCon IL-2 β/γ
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05081609 | Jan 2022 → Aug 2027 expected | HER2 positive breast carcinoma, cervical carcinoma, melanoma, metastatic neoplasm +2 | Ascendis Pharma A/S | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransCon IL-2 β/γ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05081609 ↗ |
| Action | Activate | “IL-2 β/γ demonstrated selective and potent human IL-2Rβ/γ binding and activation without IL-2Rα interactions.” PMID 35817480 ↗ Jul 2022 |
| Modality | Protein / enzyme biologic | “TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2.” PMID 35817480 ↗ Jul 2022 |
| Route | Intravenous | “TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion” NCT05081609 ↗ |